Mankind Pharma In-Licenses Two Insulin Analogues from China for Indian Market
Mankind Pharma has signed an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for Insulin Degludec and Insulin Degludec plus Aspart combination in India, strengthening its injectable diabetes portfolio.
Licensing And Marketing Agreement | 20/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy